AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2026-03-10T20:02:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Insiders Pour Millions into These 3 Stocks — Here’s Why They Draw Plaudits Across the Board
Fri 23 May 25, 10:02 AMJazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings May Just Be The Starting Point
Thu 15 May 25, 10:58 AMPharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Wed 14 May 25, 03:31 AMUnlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects
Tue 13 May 25, 01:16 PMPharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
Fri 09 May 25, 12:51 PMAppeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fight
Wed 07 May 25, 03:00 PMHere's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings
Tue 06 May 25, 10:30 PMJazz Pharmaceuticals (NASDAQ:JAZZ) Misses Q1 Sales Targets
Tue 06 May 25, 09:49 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -372.78400M | -112.83800M | 275.10M | 454.30M | 529.46M |
| Minority interest | - | - | - | - | - |
| Net income | -214.13900M | -328.95400M | 238.62M | 523.37M | 447.10M |
| Selling general administrative | 1416.97M | 1451.68M | 854.23M | 736.94M | 683.53M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 3118.86M | 2653.48M | 2214.65M | 2033.83M | 1769.38M |
| Reconciled depreciation | 629.47M | 552.48M | 278.25M | 370.16M | 216.73M |
| Ebit | 512.27M | 170.28M | 765.46M | 532.37M | 657.73M |
| Ebitda | 1111.44M | 696.05M | 1025.04M | 997.16M | 859.23M |
| Depreciation and amortization | 599.17M | 525.77M | 259.58M | 464.79M | 201.50M |
| Non operating income net other | -28.93500M | -5.06400M | -6.23300M | - | -9.07800M |
| Operating income | 512.27M | 170.28M | 765.46M | 532.37M | 614.84M |
| Other operating expenses | 3147.11M | 2923.96M | 1598.11M | 1519.41M | 1233.19M |
| Interest expense | 288.24M | 278.77M | 99.71M | 72.26M | 77.08M |
| Tax provision | -158.64500M | 216.12M | 33.52M | -73.15400M | 80.16M |
| Interest income | - | - | - | 82.16M | 86.15M |
| Net interest income | -288.24200M | -278.76600M | -99.70700M | -72.26100M | -77.07500M |
| Extraordinary items | - | - | - | - | 0.00750M |
| Non recurring | 577.80M | - | 387.39M | - | 42.90M |
| Other items | - | - | - | - | - |
| Income tax expense | -158.64500M | 216.12M | 33.52M | -73.15400M | 80.16M |
| Total revenue | 3659.37M | 3094.24M | 2363.57M | 2161.76M | 1890.92M |
| Total operating expenses | 2606.59M | 2483.20M | 1449.19M | 1391.48M | 1111.64M |
| Cost of revenue | 540.52M | 440.76M | 148.92M | 127.93M | 121.54M |
| Total other income expense net | -885.05200M | -283.11600M | -490.36700M | -78.07200M | -51.19600M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -214.13900M | -329.66800M | 241.58M | 523.37M | 449.30M |
| Net income applicable to common shares | -224.06000M | -329.66800M | 238.62M | 523.37M | 447.10M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 11393.36M | 10835.25M | 12298.64M | 6535.90M | 5538.90M |
| Intangible assets | 5418.04M | 5794.44M | 7152.33M | 2195.05M | 2440.98M |
| Earning assets | - | - | - | - | - |
| Other current assets | 334.78M | 267.19M | 252.39M | 152.49M | 78.89M |
| Total liab | 7656.36M | 7749.52M | 8333.45M | 2876.16M | 2427.92M |
| Total stockholder equity | 3737.00M | 3085.73M | 3965.19M | 3659.74M | 3110.98M |
| Deferred long term liab | - | 944.34M | 12.03M | 130.40M | 7.43M |
| Other current liab | 774.47M | 810.97M | 675.91M | 377.93M | 278.84M |
| Common stock | 0.06M | 0.06M | 0.06M | 0.06M | 0.06M |
| Capital stock | 0.06M | 0.06M | 0.06M | 0.06M | 0.06M |
| Retained earnings | 878.66M | 733.59M | 830.23M | 1159.89M | 1067.82M |
| Other liab | - | 1045.94M | 1418.00M | 233.86M | 337.67M |
| Good will | 1753.13M | 1692.66M | 1827.61M | 958.30M | 920.02M |
| Other assets | - | 435.14M | 363.94M | 415.04M | 272.24M |
| Cash | 1206.31M | 881.48M | 591.45M | 1057.77M | 637.34M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1536.69M | 933.19M | 809.30M | 653.75M | 364.49M |
| Current deferred revenue | 35.07M | 0.46M | 2.09M | 2.55M | 4.72M |
| Net debt | 4590.34M | 4914.70M | 5545.69M | 1177.10M | 1121.14M |
| Short term debt | 624.40M | 31.00M | 31.00M | 246.32M | 33.39M |
| Short long term debt | 604.95M | 31.00M | 31.00M | 246.32M | 33.39M |
| Short long term debt total | 5796.65M | 5796.18M | 6137.14M | 2234.87M | 1758.48M |
| Other stockholder equity | 3699.95M | 3477.60M | 3535.26M | 2634.14M | 2266.50M |
| Property plant equipment | - | 301.38M | 343.42M | 127.94M | 270.89M |
| Total current assets | 3263.92M | 2606.14M | 2611.33M | 2839.57M | 1630.27M |
| Long term investments | - | - | - | - | 4.50M |
| Net tangible assets | - | -4329.52700M | -5014.74600M | 648.74M | -250.01400M |
| Short term investments | 420.00M | - | 0.00000M | 1075.00M | 440.00M |
| Net receivables | 705.79M | 651.49M | 563.36M | 396.49M | 355.99M |
| Long term debt | 5107.99M | 5693.34M | 6018.94M | 1848.52M | 1573.87M |
| Inventory | 597.04M | 714.06M | 1072.72M | 95.40M | 78.61M |
| Accounts payable | 102.75M | 90.76M | 100.30M | 26.95M | 47.55M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -841.67400M | -1125.50900M | -400.36000M | -134.35200M | -223.39300M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.00600M | 0.00600M | 0.06M | 0.06M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 733.59M | 830.23M | 1159.89M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 240.75M | 64.39M | 40.81M | 25.72M | 47.91M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 8129.44M | 8229.11M | 9687.31M | 3696.33M | 3908.63M |
| Capital lease obligations | 78.67M | 87.78M | 102.96M | 154.49M | 163.95M |
| Long term debt total | - | 5693.34M | 6018.94M | 1848.52M | 1573.87M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -589.23800M | -1.03600M | 1068.18M | -642.67500M | -155.30000M |
| Change to liabilities | - | 141.68M | 54.72M | 64.61M | -0.64400M |
| Total cashflows from investing activities | - | -446.23000M | -5212.14300M | -1007.67000M | -155.30000M |
| Net borrowings | - | -582.01400M | 3870.86M | 591.81M | -33.38700M |
| Total cash from financing activities | -305.25400M | -529.49100M | 3970.52M | 528.07M | -293.74500M |
| Change to operating activities | - | 164.69M | 54.45M | -5.63600M | -38.46900M |
| Net income | 414.83M | -224.06000M | -329.66800M | 238.62M | 523.37M |
| Change in cash | 354.83M | 290.03M | -466.32100M | 420.43M | 327.72M |
| Begin period cash flow | 851.48M | 591.45M | 1057.77M | 637.34M | 309.62M |
| End period cash flow | 1206.31M | 881.48M | 591.45M | 1057.77M | 637.34M |
| Total cash from operating activities | 1092.01M | 1271.98M | 778.51M | 899.65M | 776.40M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 638.70M | 629.47M | 552.48M | 278.25M | 370.16M |
| Other cashflows from investing activities | - | -416.14800M | -5212.14300M | -349.99100M | -1007.67000M |
| Dividends paid | - | 98.02M | 99.66M | 99.68M | 57.83M |
| Change to inventory | -13.42000M | -49.64200M | -48.86100M | -30.53700M | -32.79000M |
| Change to account receivables | -51.88300M | -90.13500M | -92.73500M | -38.64700M | -92.32600M |
| Sale purchase of stock | -269.76100M | -0.05400M | -35.60200M | -146.53700M | -301.45000M |
| Other cashflows from financing activities | -50.95200M | 52.58M | 5291.12M | 1564.18M | 41.09M |
| Change to netincome | - | 139.12M | 603.64M | 155.22M | -9.34500M |
| Capital expenditures | 23.96M | 498.19M | 45.53M | 379.25M | 182.34M |
| Change receivables | - | -90.13500M | -92.73500M | -38.64700M | - |
| Cash flows other operating | - | 725.54M | 137.82M | 175.47M | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 296.26M | -463.11400M | 420.05M | - |
| Change in working capital | -204.43900M | 9.90M | -47.95200M | -85.43700M | -150.08400M |
| Stock based compensation | 226.84M | 222.00M | 189.01M | 121.00M | 110.56M |
| Other non cash items | 276.29M | 926.92M | 345.44M | 484.15M | 159.01M |
| Free cash flow | 1068.05M | 773.78M | 732.98M | 520.39M | 594.07M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals PLC |
0.53 0.29% | 185.93 | 21.98 | 5.93 | 1.80 | 1.84 | 2.88 | 9.02 |
| NVO Novo Nordisk A/S |
-1.06 2.66% | 38.72 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
- -% | 38.88 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
38.30 8.31% | 499.17 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-9.57 1.22% | 772.03 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Waterloo Exchange, Dublin, Ireland, D04 E5W7
| Name | Title | Year Born |
|---|---|---|
| Mr. Bruce C. Cozadd | Co-Founder, Chairman & CEO | 1964 |
| Mr. Daniel N. Swisher Jr. | Pres & COO | 1963 |
| Ms. Renee D. Gala | Exec. VP & CFO | 1972 |
| Dr. Robert Iannone M.D. | Exec. VP and Global Head of R&D | 1967 |
| Ms. Patricia Carr | Sr. VP & Chief Accounting Officer | 1971 |
| Dr. Finbar Larkin Ph.D. | Sr. VP of Technical Operations | 1958 |
| Ms. Andrea N. Flynn Ph.D. | VP & Head of Investor Relations | NA |
| Ms. Neena M. Patil J.D. | Exec. VP & Chief Legal Officer | 1975 |
| Dr. George Christopher Eliades Ph.D. | Sr. VP of Corp. Devel. & Chief Transformation Officer | 1970 |
| Ms. Heidi Manna | Sr. VP & Chief HR Officer | 1972 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...